LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects

Journal of Psychopharmacology

Volumn 29, Issue 1, 2015, Pages 57-68

  Gasser, Peter ^a   Kirchner, Katharina ^b   Passie, Torsten ^c  

^a Practice for Psychiatry and Psychotherapy   (Switzerland)

^b Dietikon ^*  (Switzerland)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

hallucinogens; LSD; psychedelics; psycho oncology; psycholytic therapy

Indexed keywords

LYSERGIDE; PLACEBO;

ADULT; ADVERSE OUTCOME; AGED; ANXIETY DISORDER; ARTICLE; ATTITUDE TO HEALTH; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EMOTIONALITY; FEMALE; HUMAN; LIFE THREAT; MALE; MIGRAINE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEOPLASM; NEUROLOGIC DISEASE; PERSONAL EXPERIENCE; PERSONAL VALUE; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PSYCHOTHERAPY; QUALITATIVE RESEARCH; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHEUMATIC DISEASE; SEMI STRUCTURED INTERVIEW; SOCIAL PSYCHOLOGY; SPIELBERGER STATE AND TRAIT ANXIETY INVENTORY FORM X; ANXIETY DISORDERS; CLINICAL TRIAL; COMPLICATION; EMOTION; FOLLOW UP; MIDDLE AGED; PROCEDURES; PSYCHOLOGY; TREATMENT OUTCOME;

ADULT; ANXIETY DISORDERS; DOUBLE-BLIND METHOD; EMOTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYSERGIC ACID DIETHYLAMIDE; MALE; MIDDLE AGED; NEOPLASMS; PSYCHOTHERAPY; QUALITATIVE RESEARCH; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84918532648     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881114555249     Document Type: Article

References (73)

1. The Use of LSD in Psychotherapy and Alcoholism. Abramson H, ed. New York: Bobbs-Merrill ; 1967 :
2. Adlam J, Zaman R. The role of BDNF and memory in major depressive disorder. Psychiatr Danub. 2013 ; 2013: S368 - S369
3. Behrendt RP. Hallucinations: Synchronisation of thalamocortical gamma oscillations underconstrained by sensory input. Conscious Cogn. 2003 ; 12: 413-451
4. Béïque JC, Imad M, Mladenovic L, et al. Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex. Proc Natl Acad Sci U S A. 2007 ; 104: 9870-9875
5. Bullmore E, Barnes A, Bassett DS, et al. Generic aspects of complexity in brain imaging data and other biological systems. Neuroimage. 2009 ; 47: 1125-1134
6. Carhart-Harris RL, Friston KJ. The default-mode, ego-functions and free-energy: A neurobiological account of Freudian ideas. Brain. 2010 ; 133: 1265-1283
7. Carhart-Harris RL, Erritzoe D, Williams T, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A. 2012a ; 109: 2138-2143
8. Carhart-Harris RL, Leech R, Hellyer PJ, et al. The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci. 2014 ; 8: 20
9. Carhart-Harris RL, Leech R, Williams TM, et al. Implications for psychedelic-assisted psychotherapy: Functional magnetic resonance imaging study with psilocybin. Br J Psychiatry. 2012b ; 200: 238-244
10. Cohen J. Lysergic acid diethylamide: Side effects and complications. J Nerv Ment Dis. 1960 ; 130: 30-40
11. Cyr M1, Landry M, Di Paolo T. Modulation by estrogen-receptor directed drugs of 5-hydroxytryptamine-2A receptors in rat brain. Neuropsychopharmacology. 2000 ; 23: 69-78
12. Diesch M LSD: Rückkehr in die klinische Forschung. Solothurn: Nachtschatten ; 2014, in print:
13. Eliade M Schamanismus und archaische Ekstasetechnik. Frankfurt: Suhrkamp ; 1975:
14. Fiorella D, Rabin RA, Winter JC. The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. I: Antagonist correlation analysis. Psychopharmacology (Berl). 1995 ; 121: 347-356
15. Gasser P. Die Psycholytische Therapie in der Schweiz von 1988-1993. Schweiz Arch Neurol Psych. 1996 ; 147: 59-65
16. Gasser P, Holstein D, Michel Y, et al. Safety and efficacy of LSD-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014 ; 202: 513-520
17. Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, et al. Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology. 1999 ; 20: 565-581
18. Griffiths RR, Johnson MW, Richards WA, et al. Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology. 2011 ; 218: 649-665
19. Griffiths RR, Richards WA, McCann U, et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology. 2006 ; 187: 268-283
20. Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiat. 2011 ; 68: 71-78
21. Grof S Realms of the Human Unconscious. New York, NY: Viking ; 1975:
22. Grof S LSD Psychotherapy. Pomona, CA: Hunter House ; 1980:
23. Grof S, Goodman LE, Richards WA, et al. LSD-assisted psychotherapy in patients with terminal cancer. Int Pharmacopsychiatry. 1973 ; 8: 129-144
24. Gusnard DA, Akbudak E, Shulman, et al. Medial prefrontal cortex and self-referential mental activity: relation to a default mode of brain function. Proc Natl Acad Sci U S A. 2007 ; 98: 4259-64
25. Hagmann P, Cammoun L, Gigandet X, et al. Mapping the structural core of human cerebral cortex. PLoS Biol. 2008 ; 6: e159
26. Halberstadt AL, Geyer MA. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology. 2011 ; 61: 364-381
27. Hariri AR, Drabant EM, Weinberger DR. Imaging genetics: Perspectives from studies of genetically driven variation in serotonin function and corticolimbic affective processing. Biol Psychiatry. 2006 ; 59: 888-897
28. Hintzen A, Passie T The pharmacology of LSD. Oxford, UK: Oxford University Press ; 2010:
29. James W The varieties of religious experience. New York: Longmans Green ; 1902:
30. Jiang C1, Salton SR. The role of neurotrophins in major depressive disorder. Transl Neurosci. 2013 ; 4: 46-58
31. Kast E. Attenuation and anticipation: A therapeutic use of lysergic acid diethylamide. Psychiatric Quarterly. 1967 ; 41: 646-657
32. Kirchner K LSD-supported psychotherapy: effects on daily life and longterm changes. MA Thesis, University of Zurich, Switzerland: ; 2010:
33. Kurland AA. LSD in the supportive care of the terminally ill cancer patient. J Psychoactive Drugs. 1985 ; 17: 279-290
34. Leuner H Die experimentelle Psychose. Berlin, Göttingen, Heildelberg: Springer ; 1962 :
35. Leuner H The use of LSD in Psychotherapy and Alcoholism. Abramson HA, ed. New York et al.: Bobbs-Merrill, pp ; 1967: 101-116.
36. Leuner H Halluzinogene. Bern: Huber ; 1981 :
37. McGlothlin W, Cohen S, McGlothlin MS. Long lasting effects of LSD on normals. Arch Gen Psychiat. 1967 ; 17: 521-532
38. MacLean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol. 2011 ; 25: 1453-1461
39. Malleson N. Acute adverse reactions to LSD in clinical and experimental use in the United Kingdom. Brit J Psychiatry. 1971 ; 118: 229-230
40. MAPS (2007) LSD-assisted psychotherapy in persons suffering from anxiety associated with advanced-stage life threatening diseases. Study Report. Available at: http://maps.org/pdf/LDA1-FINAL-CSR-20Aug13.pdf (accessed 10 October 2014).
41. Martín-Ruiz R, Puig MV, Celada P, et al. Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J Neurosci. 2001 ; 21: 9856-9866
42. Maslow A. Lessons from the peak experience. J Humanistic Psychol. 1962 ; 2: 9-18
43. Maslow A Religions, values, and peak experiences. New York: Viking ; 1970 :
44. Maxwell JA Handbook of Applied Social Research Methods. Bickman L Rog DJ, ed. Los Angeles, CA: Sage, pp ; 2009: 214-253.
45. Die Praxis der qualitativen Inhaltsanalyse. Mayring P Glaeser-Zikuda M, ed. Weinheim: Beltz ; 2008 :
46. Meert TF Serotonin in antipsychotic treatment. Kane JM Moller H-J Awouters F, ed. New York: Marcel Dekker ; 1996: 109-130.
47. Nichols DE. Hallucinogens. Pharmacol Ther. 2004 ; 101: 131-181
48. Northoff G. Psychopathology and pathophysiology of the self in depression - neuropsychiatric hypothesis. J Affect Disord. 2007 ; 104: 1-14
49. Pahnke WN. The psychedelic mystical experience in the human encounter with death. Harvard Theol Rev. 1969 ; 62: 1-21
50. Pahnke WN, Kurland AA, Unger S, et al. The experimental use of psychedelic (LSD) psychotherapy. JAMA. 1970 ; 212: 1856-1863
51. Passie T, Halpern JH, Stichtenoth DO, et al. The pharmacology of lysergic acid diethylamide: A review. CNS Neurosci Ther. 2008 ; 14: 295-314
52. Pizzagalli DA. Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology. 2011 ; 36: 183-206
53. Pierce PA, Peroutka SJ. Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacology. 1989 ; 98: 118-122
54. Puig MV, Celada P, Díaz-Mataix L, et al. In vivo modulation of the activity of pyramidal neurons in the rat medial prefrontal cortex by 5-HT2A receptors: relationship to thalamocortical afferents. Cereb Cortex. 2003 ; 13: 870-82
55. Raichle ME. The neural correlates of consciousness: An analysis of cognitive skill learning. Philos Trans R Soc Lond B Biol Sci. 1998 ; 353: 1889-1901
56. Richards WA, Rhead JC, Dileo FB, et al. The peak experience variable in DPT-assisted psychotherapy with cancer patients. J Psychoactive Drugs. 1977 ; 9: 1-10
57. Savage C, Fadiman J, Mogar R, et al. The effects of psychedelic (LSD) therapy on values, personality, and behavior. Int J Neuropsychiatry. 1966 ; 2: 241-254
58. Schultes RE, Hofmann A Plants of the Gods: Origins of Hallucinogenic Use. London: Hutchinson ; 1980 :
59. Schlussbericht Bestandesaufnahme psychosoziale Onkologie in der Schweiz. Bern: Krebsliga Schweiz ; 2005 :
60. Sewell RA, Halpern JH, Pope HG. Response of cluster headache to psilocybin and LSD. Neurology. 2006 ; 66: 1920-1922
61. Spielberger CS, Gorsuch RL, Lushene RE Manual for the State Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press ; 1970 :
62. Stuhrmann A1, Suslow T, Dannlowski U. Facial emotion processing in major depression: A systematic review of neuroimaging findings. Biol Mood Anxiety Disord. 2011 ; 1: 10
63. Terrill, James. The nature of the LSD experience. J Nerv Ment Dis. 1962 ; 135: 425-29
64. Unger SM. Mescaline, LSD, psilocybin, and personality change. Psychiatry. 1963 ; 26: 111-125
65. Vaidya VA, Marek GJ, Aghajanian GK, et al. 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci. 1997 ; 17: 2785-2795
66. Vázquez-Borsetti P1, Cortés R, Artigas F. Pyramidal neurons in rat prefrontal cortex projecting to ventral tegmental area and dorsal raphe nucleus express 5-HT2A receptors. Cereb Cortex. 2009 ; 19: 1678-1686
67. Vollenweider FX, Geyer MA. A systems model of altered consciousness: Integrating natural and drug-induced psychoses. Brain Res Bull. 2001 ; 56: 495-507
68. Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nat Rev Neurosci. 2010 ; 11: 642-651
69. Vollenweider FX, Leenders KL, Scharfetter C, et al. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology. 1997 ; 16: 357-372
70. Vollenweider FX, Vontobel P, Hell D, et al. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man - a PET study with [11C]raclopride. Neuropsychopharmacology. 1999 ; 20: 424-433
71. Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, et al. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998 ; 9: 3897-3902
72. Weiss RS Learning from Strangers: The Art and Method of Qualitative Interview Studies. New York, NY: Free Press ; 1995 :
73. Winter JC, Eckler JR, Rabin RA. Serotonergic/glutamatergic interactions: The effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli. Psychopharmacology (Berl). 2004 ; 172: 233-240